The stock price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has jumped by 7.20 compared to previous close of 21.87. Despite this, the company has seen a fall of -1.33% in its stock price over the last five trading days. globenewswire.com reported 2025-04-01 that PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.
Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?
Moreover, the 36-month beta value for APLS is 0.84. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 3 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for APLS is 104.48M and currently, short sellers hold a 18.49% of that float. On April 01, 2025, APLS’s average trading volume was 1.81M shares.
APLS’s Market Performance
The stock of Apellis Pharmaceuticals Inc (APLS) has seen a -1.33% decrease in the past week, with a -2.56% drop in the past month, and a -28.26% fall in the past quarter. The volatility ratio for the week is 5.42%, and the volatility levels for the past 30 days are at 4.53% for APLS. The simple moving average for the past 20 days is -4.21% for APLS’s stock, with a -26.94% simple moving average for the past 200 days.
Analysts’ Opinion of APLS
Many brokerage firms have already submitted their reports for APLS stocks, with Goldman repeating the rating for APLS by listing it as a “Neutral.” The predicted price for APLS in the upcoming period, according to Goldman is $36 based on the research report published on December 17, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see APLS reach a price target of $31. The rating they have provided for APLS stocks is “Equal-Weight” according to the report published on November 21st, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to APLS, setting the target price at $25 in the report published on October 25th of the previous year.
APLS Trading at -12.51% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.87% of loss for the given period.
Volatility was left at 4.53%, however, over the last 30 days, the volatility rate increased by 5.42%, as shares sank -7.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.21% lower at present.
During the last 5 trading sessions, APLS fell by -2.00%, which changed the moving average for the period of 200-days by -45.21% in comparison to the 20-day moving average, which settled at $24.47. In addition, Apellis Pharmaceuticals Inc saw -26.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Chopas James George, who sale 183 shares at the price of $24.82 back on Mar 17 ’25. After this action, Chopas James George now owns 47,955 shares of Apellis Pharmaceuticals Inc, valued at $4,543 using the latest closing price.
Chopas James George, the Officer of Apellis Pharmaceuticals Inc, proposed sale 183 shares at $24.82 during a trade that took place back on Mar 17 ’25, which means that Chopas James George is holding shares at $4,543 based on the most recent closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -0.21 for the present operating margin
- 0.85 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -0.25. The total capital return value is set at -0.24. Equity return is now at value -93.55, with -23.64 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.19. The debt to equity ratio resting at 2.06. The interest coverage ratio of the stock is -4.08.
Currently, EBITDA for the company is -236.39 million with net debt to EBITDA at -0.38. When we switch over and look at the enterprise to sales, we see a ratio of 3.86. The receivables turnover for the company is 2.88for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.25.
Conclusion
To wrap up, the performance of Apellis Pharmaceuticals Inc (APLS) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
